List view / Grid view
Clearly what is needed is a synergistic collaboration bringing together the respective competence and expertise of academia and industry. All the major pharmaceutical companies have recognised this need and have introduced a range of different models for association with academia and small biotech or biopharma companies. Attempted solutions range from…
The ability to individualise a patient’s care has become a particularly pressing issue in the field of cancer therapeutics as there is a growing recognition that both the global incidence of cancer is steadily rising and the associated costs in terms of treatment and lost productivity are ever increasing. Advances…
Oceans cover 70 per cent of planet Earth and it is only in the 20th century that organisms from this environment began to be assessed for their potential to provide new drugs. A new marine derived pharmaceutical pipeline has started flowing, delivering new chemical entities with unique modes of action…
Preclinical drug target validation has the aim to increase confidence in a particular drug target. The process proves the initial hypothesis that a particular molecular target is key or even causative for pathogenic or symptomatic mechanisms in a disease. Several success factors seem to be of particular importance for the…
Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…
Despite the ever increasing efforts being expended for drug discovery purposes, the number of approved drugs remains relatively static. A variety of explanations have been provided to explain this observation and initiatives to remedy this situation have been implemented. Many of these initiatives are still works-in-progress and whether these will…
Justin Bryans talks to Drug Target Review about his work as Director of Drug Discovery at the Centre for Therapeutics Discovery, MRC Technology. Justin is also a member of the Drug Target Review Editorial Board.
29 October 2013 | By Kenji Schorpp, Assay Development and Screening Scientist, Helmholtz Center.
Kenji Schorpp, Assay Development and Screening Scientist, talks to Drug Target Review about his work at the Helmholtz Center...
29 October 2013 | By Drug Target Review
In every issue of Drug Target Review, we will provide an update of the latest IMI projects and EU-funded initiatives...
28 October 2013 | By Prof. Dr. James Adjaye
Prof. Dr. James Adjaye, Chair of Stem Cell Research and Regenerative Medicine and Director of the Institute for Stem Cell Research and Regenerative Medicine, Heinrich Heine University, talks to Drug Target Review about his research background, why he believes Drug Target Review will be a success and why he decided…
